MoonLake Immunotherapeutics MLTX
Updated: 18 Jun 2026
No signal published yet
We already track MoonLake Immunotherapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow MoonLake Immunotherapeutics? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow MoonLake Immunotherapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In May 2026, the company announced it had reached alignment with the FDA on the regulatory pathway for its Biologics License Application (BLA) for sonelokimab in hidradenitis suppurativa. The company plans to submit the BLA in the third quarter of 2026 following a successful final pre-BLA meeting.
What Firelda Watch includes for MoonLake Immunotherapeutics
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow MoonLake Immunotherapeutics? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow MoonLake Immunotherapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more